Trial Profile
A Phase 2 Study to Evaluate the Efficacy of GS-9131 Functional Monotherapy in HIV-1-Infected Adults Failing a Nucleos(t)Ide Reverse Transcriptase Inhibitor-Containing Regimen With Nucleos(t)Ide Reverse Transcriptase Inhibitor Resistant Virus
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Rovafovir etalafenamide (Primary) ; Antiretrovirals; Bictegravir; Darunavir; Non-nucleoside reverse transcriptase inhibitors; Nucleoside reverse transcriptase inhibitors; Nucleotide reverse transcriptase inhibitors; Ritonavir
- Indications HIV-1 infections
- Focus Therapeutic Use
- Sponsors Gilead Sciences
- 24 Apr 2020 Status changed from active, no longer recruiting to discontinued.
- 08 Oct 2019 Status changed from recruiting to active, no longer recruiting.
- 27 Aug 2019 Planned number of patients changed from 68 to 69.